Methods Herein, we defined vulnerable as the group of patients with NSCLC and
performance status (PS)≥ 2 (poor PS), advanced age (≥ 75 years), or cancer cachexia. We …

Introduction Fatigue and malaise are commonly associated with a wide range of medical
conditions, including rheumatoid arthritis (RA). Evidence suggests that fatigue and malaise …

Anamorelin, developed for the treatment of cancer cachexia, is an orally active medication
that improves appetite and food intake, thereby increasing body mass and physical …

Simple Summary Synchronous oligometastatic non-small cell lung cancer (NSCLC)
represents an intermediate state of metastatic disease with a limited number of metastases …

Introduction Cancer cachexia is a complex problem characterized by weight loss due to
skeletal muscle and adipose tissue reduction. The purpose of this meta-analysis is to …

Background: Limited data exist on the impact of immunotherapy use in ethnic minority
patients with non–small cell lung cancer (NSCLC), because they have been …

Simple Summary Cancer is a major burden of disease worldwide, with cancer cachexia
being a poor prognosis factor which leads to a decreased quality of life and overall survival …

Background Elevated platelet lymphocyte ratio (PLR) and low body mass index (BMI) are
associated with inferior survival in non-small cell lung cancer (NSCLC) patients receiving …

Simple Summary We investigated the prognostic significance of the newly created Global
Immune-Nutrition-Inflammation Index (GINI) in IIIC non-small cell lung cancer (NSCLC) …

Cancer cachexia is a complex malnutrition syndrome that causes progressive dysfunction.
This syndrome is accompanied by protein and energy losses caused by reduced nutrient …